From Light-Touch to Structured Oversight
For decades, Singapore’s health supplement and traditional medicine sectors operated under a deliberately permissive regulatory regime. Health supplements are not subject to pre-market approval or licensing by the Health Sciences Authority (HSA) for importation, manufacture, or sale. Dealers carry the obligation to ensure products are safe and compliant, but the onus falls on self-assessment rather than government vetting.
That era is drawing to a close.
On 1 July 2026, HSA launched a public consultation on a proposed regulatory framework for Complementary Health Products (CHPs) under the Health Products Act 2007. The consultation period ran until 29 July 2026, and the framework is slated for phased implementation beginning in the third quarter of 2028, with full implementation targeted for the third quarter of 2030.
What Counts as a CHP?
The proposed framework covers a broad spectrum of products: health supplements, traditional medicines (excluding Traditional Chinese Medicines, which have separate oversight), homeopathic medicines, medicated oils, balms, plasters, and topical antiseptics. This is a significant expansion of the regulatory perimeter. Brands that have historically operated with minimal regulatory engagement will now face structured requirements.
The Three Pillars of the New Framework
The proposed regulatory framework is built on three core objectives: safeguarding public health, strengthening regulatory oversight, and supporting industry innovation. Specific measures include:
Mandatory product traceability. Companies will be required to maintain records that allow products to be traced through the supply chain. This addresses a longstanding gap in Singapore’s light-touch regime, where post-market surveillance relied heavily on voluntary reporting.
Safety reporting obligations. The framework introduces formalised adverse event reporting requirements, moving beyond the current system where HSA monitors adverse events reported by healthcare professionals on a largely ad hoc basis.
Advertisement controls. Health supplements are already prohibited from being labelled, advertised, or promoted for any medicinal purpose. The new framework will formalise and potentially expand these restrictions under the HPA’s statutory framework.
A Two-Year Grace Period
Recognising the compliance burden, HSA has built in a two-year grace period for product notification and other new requirements, allowing businesses sufficient time to align their existing products and processes. The phased approach—beginning with record-keeping, safety reporting, and advertisement controls in 2028, followed by product notification requirements—reflects an understanding that abrupt regulatory shifts can destabilise supply chains.
Why This Matters for the Herbal Sector
For herbal and botanical supplement brands, the framework represents both a challenge and an opportunity. The challenge is evident: increased documentation, traceability systems, and compliance infrastructure will raise operating costs, particularly for smaller importers and boutique brands.
The opportunity lies in market consolidation and consumer trust. A regulated market with mandatory traceability will disadvantage low-quality, grey-market products while rewarding brands that can demonstrate sourcing transparency, standardised extracts, and safety documentation. The current import decline—-21.37% from 2023 to 2024—may partly reflect this transition, as marginal players exit ahead of regulatory tightening.
The Strategic Imperative
Companies dealing with CHPs “should closely monitor the regulatory developments to ensure that they are in a position to comply with any new or expanded regulatory requirements,” Baker McKenzie advises in its July 2026 analysis.
For herbal brands with Singapore ambitions, the message is clear: the era of passive compliance is ending. Those who invest early in traceability, safety documentation, and regulatory engagement will be positioned to capture share as the market matures. The SGD 490 million herbal supplement market of 2033 will belong to brands that treat regulation not as a burden, but as a competitive moat.
